EP1161255A4 - Procedes et compositions pour le traitement de la dyserection - Google Patents

Procedes et compositions pour le traitement de la dyserection

Info

Publication number
EP1161255A4
EP1161255A4 EP00916081A EP00916081A EP1161255A4 EP 1161255 A4 EP1161255 A4 EP 1161255A4 EP 00916081 A EP00916081 A EP 00916081A EP 00916081 A EP00916081 A EP 00916081A EP 1161255 A4 EP1161255 A4 EP 1161255A4
Authority
EP
European Patent Office
Prior art keywords
dyserection
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00916081A
Other languages
German (de)
English (en)
Other versions
EP1161255A2 (fr
Inventor
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1161255A2 publication Critical patent/EP1161255A2/fr
Publication of EP1161255A4 publication Critical patent/EP1161255A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP00916081A 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection Withdrawn EP1161255A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324499P 1999-03-08 1999-03-08
US123244P 1999-03-08
PCT/US2000/005711 WO2000053148A2 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection

Publications (2)

Publication Number Publication Date
EP1161255A2 EP1161255A2 (fr) 2001-12-12
EP1161255A4 true EP1161255A4 (fr) 2002-07-17

Family

ID=22407530

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00916081A Withdrawn EP1161255A4 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection

Country Status (4)

Country Link
EP (1) EP1161255A4 (fr)
AU (1) AU3724400A (fr)
CA (1) CA2362918A1 (fr)
WO (1) WO2000053148A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
NO20002097L (no) * 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
NZ516616A (en) 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7115628B2 (en) * 2001-07-18 2006-10-03 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
EP0611248B1 (fr) * 1993-02-10 2000-03-22 B.M.R.A. Corporation B.V. Compositions pharmaceutiques pour le traitement de l'impuissance, contenant un inhibiteur d'alpha-adrénocepteur et un inhibiteur d'alpha-2 adrénocepteur
EP0696919B1 (fr) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnostic et traitement des dysfonctionnements erectiles
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU759825B2 (en) * 1997-12-16 2003-05-01 Pfizer Products Inc. Combination effective for the treatment of impotence
EP1059926A2 (fr) * 1997-12-18 2000-12-20 SCOTT, Nathan Earl COMBINAISON DE PROSTAGLANDINES E 2?/F 2$g(a)?, DESTINEE AU TRAITEMENT DE L'IMPUISSANCE ET A L'ACCROISSEMENT DE L'EXCITATION SEXUELLE
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
WO1999059584A1 (fr) * 1998-05-20 1999-11-25 Schering Corporation Combinaison de phentolamine et d'inhibiteurs de la phosphodiesterase gmp cyclique utilises dans le traitement des dysfonctions sexuelles
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEDLUND-H ET AL.: "Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application methods", SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, vol. 179, no. Suppl, 1996, pages 129 - 138, XP001064596 *
HUNTER WESSELS ET AL.: "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study", THE JOURNAL OF UROLOGY, vol. 160, 1998, pages 389 - 393, XP001064550 *
See also references of WO0053148A3 *

Also Published As

Publication number Publication date
WO2000053148A3 (fr) 2000-12-14
AU3724400A (en) 2000-09-28
CA2362918A1 (fr) 2000-09-14
WO2000053148A2 (fr) 2000-09-14
EP1161255A2 (fr) 2001-12-12

Similar Documents

Publication Publication Date Title
EP1628530A4 (fr) Procedes et compositions pour la prevention et le traitement de la sepsie
EP0866710A4 (fr) Compositions et procedes pour le traitement des deficits osseux
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
EP1438062A4 (fr) Methodes et compositions pour le traitement de lesions cutanees
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
EP1471874A4 (fr) Compositions et procedes d'administration pour le traitement des rides, des ridules et de l'hyperhidrose
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
EP1468118A4 (fr) Procedes et compositions pour le traitement du cancer
EP1575577A4 (fr) Composition pour la prevention et le traitement de l'inflammation de l'oreille
EP1383527A4 (fr) Procedes et compositions de traitement de lesions buccales et oesophagiennes
MA26618A1 (fr) Composes et compositions pharmaceutiques pour le traitement du paludisme
ID27191A (id) Metode untuk pengobatan insomnia
EP1560593A4 (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
EP0975654A4 (fr) Compositions et procedes pour le traitement des infections par le cytomegalovirus
EP1359885A4 (fr) Inhibiteurs de nos pour le traitement des rides
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
EP1156799A4 (fr) Traitement de la bpco
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
EP1575503A4 (fr) Compositions et procedes de traitement et de prevention d'infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20011008;LT PAYMENT 20011008;LV PAYMENT 20011008;MK PAYMENT 20011008;RO PAYMENT 20011008;SI PAYMENT 20011008

A4 Supplementary search report drawn up and despatched

Effective date: 20020531

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/08 A, 7A 61K 31/415 B, 7A 61K 31/505 B, 7A 61K 38/12 B, 7A 61P 15/10 B, 7A 61K 38/12 J, 7A 61K 31:00 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020823